Prot #209626: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)

Project: Research project

Project Details

StatusFinished
Effective start/end date3/10/21 → 3/10/24

Funding

  • Quintiles, Inc. ((OE) Prot #209626 // (OE) Prot #209626)
  • GlaxoSmithKline LLC ((OE) Prot #209626 // (OE) Prot #209626)